International Conference on Afghanistan, London (2006)

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
星期二, 八月 8, 2023
CCCC, Pharming, G&A, BRAF V600, Patient, Research and development, R, Disease, Multiple myeloma, Drug discovery, Lung cancer, Combination therapy, International Conference on Afghanistan, London (2006), Security (finance), BRD9, FDA, Conference, Safety, Appointment, Roche, BRAF, Medicine, NSCLC, Finance, Controlled Impact Demonstration, Administration, Colorectal cancer, Research, Therapy, Synovial sarcoma, Drug development, CRC, ICML, Clinical trial, Lymphoma, NHL, CNS, Dexamethasone, ASCO, Public expenditure, American Society of Clinical Oncology, Melanoma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Food, Pharmaceutical industry, Cryptocurrency, Fine chemical, Vaccine, Video game, Biogen, Calico, IND, Mutant

WATERTOWN, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today reported financial results for the second quarter ended June 30, 2023, as well as recent business highlights.

Key Points: 
  • Revenue: Total revenue for the second quarter of 2023 was $2.7 million, compared to $13.8 million for the second quarter of 2022.
  • Research and Development (R&D) Expense: R&D expense for the second quarter of 2023 was $29.9 million, compared to $31.3 million for the second quarter of 2022.
  • General and Administrative (G&A) Expense: G&A expense for the second quarter of 2023 was $10.3 million, compared to $9.9 million for the second quarter of 2022.
  • Net loss per share for the second quarter of 2023 was $0.73 compared to $0.56 for the second quarter of 2022.

Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
星期四, 五月 11, 2023
Teva Pharmaceuticals, Patent, Metal, Human, Gian Maria Annovi, PD, Alzheimer's disease, Environmental Toxicology and Pharmacology, United States Patent and Trademark Office, Clinical trial, Toxicology, ATM, Down syndrome, International Conference on Afghanistan, London (2006), Patient, Procházka, Process chemistry, Mouse, Research, AD, FDA, News, NYSE, Conference, Chemical process, Pharmaceutical industry, EU, Pharmacology

BERWYN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company addressing neurodegenerative diseases, announced first quarter financial results for the period ended March 31, 2023, and reviewed recent accomplishments.

Key Points: 
  • BERWYN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company addressing neurodegenerative diseases, announced first quarter financial results for the period ended March 31, 2023, and reviewed recent accomplishments.
  • At a recent R&D webcast on April 20, 2023, the Company:
    Reviewed its ongoing clinical programs in AD and PD.
  • Explained the results from the pre-planned blinded interim analysis of the ongoing Phase 3 study for early PD, announced on March 31, 2023.
  • Financial Results (for the quarter ending March 31, 2023)
    Cash and cash equivalents were $16.8 million.

DarioHealth Reports First Quarter Financial and Operating Results

Retrieved on: 
星期四, 五月 11, 2023
Well, CGM, ATTD, Partnership, Type 2 diabetes, Pharmacy, Therapy, Digital, Dexcom, GAAP, Research, Ratio, B2C, Back pain, Hospital, Acquisition, International Conference on Afghanistan, London (2006), Amwell, Pharmacy benefit management, Pain management, PBM, Webcast, Sanofi, Depreciation, Growth, Himawari (satellites), Advanced Technology Vehicles Manufacturing Loan Program, Conference, Diabetes, Total, Video game, Retail, Marketing, Pharmaceutical industry, Dario

ET today

Key Points: 
  • ET today
    NEW YORK, May 11, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today reported financial results for the first quarter 2023 and provided a corporate and commercial update.
  • "Business-to-Business (B2B) revenues continued to increase, representing approximately 70% of our total revenue during the first quarter, up from 56% in the first quarter of 2022.
  • Total operating expenses excluding stock-based compensation, acquisition expenses, earn-out measurement, and depreciation for the first quarter of 2023 were $10.6 million, compared to $14.8 million for the first quarter of 2022, and $10 million for the fourth quarter of 2022.
  • Operating loss excluding stock-based compensation, acquisition expenses and depreciation for the first quarter of 2023 were $6.3 million compared to $9.9 million for the first quarter of 2022, and $6.0 million for the fourth quarter of 2022.

Orvana Exhibits at 2022 PDAC Toronto, Canada

Retrieved on: 
星期一, 六月 13, 2022
Prospectors, Public expenditure, Climate Disclosure Standards Board, Mission statement, Mining, Prospectors & Developers Association of Canada, Copper, Company, Tax, Conference, PEA, Legislation, Forward-looking statement, News, Failure, ORV, Organization, Metro Toronto Convention Centre, Maintenance, IEX, Conversation, Silver, Growth, International Conference on Afghanistan, London (2006), Area studies, Infection, COVID-19, Risk, TSX, PDAC, Phrase, Association, Gold, Daniel Rendón Herrera, Oxide, Risk management, San Vicente de Tagua Tagua

TORONTO, June 13, 2022 /PRNewswire/ -- Orvana Minerals Corp. (TSX: ORV) (the "Company" or "Orvana") is pleased to announce that it will be exhibiting at the 2022 Prospectors and Developers Association of Canada (PDAC) International Conference being held in Toronto at the Metro Toronto Convention Centre from June 13 to 15, 2022.

Key Points: 
  • TORONTO, June 13, 2022 /PRNewswire/ -- Orvana Minerals Corp. (TSX: ORV) (the "Company" or "Orvana") is pleased to announce that it will be exhibiting at the 2022 Prospectors and Developers Association of Canada (PDAC) International Conference being held in Toronto at the Metro Toronto Convention Centre from June 13 to 15, 2022.
  • Orvana cordially invites shareholders, investors, brokers, analysts, and interested parties, to learn more about its operations and growth perspectives via brownfield and greenfield exploration programs, by visiting booth #2243 in the Investors Exchange area of PDAC.
  • The PDAC International Convention, Trade Show & Investors Exchange is the world's leading convention for people, companies and organizations in, or connected with, mineral exploration.
  • For more information about the conference, visit: http://pdac.ca/convention
    ABOUT ORVANA - Orvana is a multi-mine gold-copper-silver company.

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference

Retrieved on: 
星期二, 五月 17, 2022
American Thoracic Society, International Conference on Afghanistan, London (2006), Adult, SH, KROS, Patient, Biology, Rat, PAH, Therapy, Hypertensive emergency, Lists of diseases, Research, RATS, Conference, Male, GLOBE, Pharmaceutical industry

Additional data from a separate nonclinical study in cynomolgus monkeys was also included in the presentation.

Key Points: 
  • Additional data from a separate nonclinical study in cynomolgus monkeys was also included in the presentation.
  • RKER-012 prevented increased pulmonary arterial pressure and right ventricle hypertrophy in a rodent PAH model and KER-012 did not alter red blood cell number in non-human primates.
  • A research form of KER-012 (RKER-012) was tested in this SUGEN/hypoxia (SH) rat model of PAH.
  • Treatment of the SH rats with ActRIIA-Fc attenuated increased Fulton index (p

The iLet® Bionic Pancreas Significantly Reduced HbA1c and Improved Time in Range vs Standard of Care for a Diverse Range of People with Type 1 Diabetes

Retrieved on: 
星期六, 四月 30, 2022
People, LinkedIn, White, Sale, FDA, Boston University, American Diabetes Association, Randomized controlled trial, Quality of life, Glucagon, Ageing, Standard of care, CGM, National, Risk, Ilet, Review, Regulation of tobacco by the U.S. Food and Drug Administration, Instagram, Medical Affairs Bureau, Safety, IDE, Human, Harvard Medical School, GLOBE, ATTD, Food, Meal, Interim, Treatment, Adult, Honda advanced technology, Infant, Twitter, Technology, Conference, Insulin, Hypoglycemia, Population, International Conference on Afghanistan, London (2006), Associate, IO, YouTube, Federal, ADA, FNP, AID, Bionics, Medical imaging, Pharmaceutical industry, Glycated hemoglobin, Diabetes, CONCORD, Medicine

The pivotal trial was designed to test the safety and efficacy of the iLet Bionic Pancreas relative to a standard of care control group over a 13-week study period.

Key Points: 
  • The pivotal trial was designed to test the safety and efficacy of the iLet Bionic Pancreas relative to a standard of care control group over a 13-week study period.
  • The trial was conducted in a home-use setting and enrolled 440 adults and children aged 6 years and older with type 1 diabetes.
  • In an analysis of participants who had a baseline HbA1C greater than 7%, there was a 0.7% reduction of HbA1c in the iLet Bionic Pancreas arm vs standard of care.
  • Caution: The iLet Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use.

Shineco, Inc. Announces Strategic Alliance to Enhance the Research and Development of Innovative Drugs and Medical Devices

Retrieved on: 
星期四, 二月 17, 2022
NASDAQ, CEO, Textile, Company, SISI, Economic development, U.S. Securities and Exchange Commission, Solution, Security (finance), R, International Conference on Afghanistan, London (2006), Goal, Clinical trial, GLOBE, National Medical Products Administration, CRO, JSY, Digital technology, Marketing, Pharmaceutical industry, Research, Conference, COVID-19, Industry, Medical device

Both parties plan to promote innovative drugs and medical devices and support the establishment of Shineco pharmaceutical R&D and innovation center.

Key Points: 
  • Both parties plan to promote innovative drugs and medical devices and support the establishment of Shineco pharmaceutical R&D and innovation center.
  • JSY is a professional outsourcing service company engaged in comprehensive drugs and medical devices development.
  • Ms. Qiulan Yang, the CEO of JSY, commented, We are very pleased to enter into the strategic cooperation with Shineco to jointly develop the innovative drugs and medical devices.
  • With the JSY's expertise, Shineco expects to enhance its R&D capability in innovative drugs and medical devices and plans to establish a pharmaceutical R&D and innovation center to accelerate the development of innovative drugs and medical devices with the goal of satisfying additional clinical needs in China.

A Russian women's movement stood up for white asbestos (chrysotile)

Retrieved on: 
星期四, 二月 10, 2022
Industry, Rotterdam Convention, International Alliance of Theatrical Stage Employees, Woman, Conference, International Conference on Afghanistan, London (2006), Safety, Population, Drinking water, Mining, Party, Movement, Asbestos, Health, Organization, Environment, Chrysotile, Social, Personal protective equipment, Public health, Convention, Economic development, Oil, Arctic

They deemed it necessary to organize an international conference where measures to protect the industrial use of chrysotile asbestos from discriminations would be developed.

Key Points: 
  • They deemed it necessary to organize an international conference where measures to protect the industrial use of chrysotile asbestos from discriminations would be developed.
  • Chrysotile asbestos is a fibrous mineral widely used in industrial production.
  • However, the industrial use of chrysotile asbestos is regularly opposed by several states and activists during the Conference of Parties of Rotterdam convention.
  • In 2019, the chrysotile industry weathered a storm and stood proud opponents of asbestos failed to provide convincing evidence.

A Russian women's movement stood up for white asbestos (chrysotile)

Retrieved on: 
星期四, 二月 10, 2022
Industry, Rotterdam Convention, International Alliance of Theatrical Stage Employees, Woman, Conference, International Conference on Afghanistan, London (2006), Safety, Population, Drinking water, Mining, Party, Movement, Asbestos, Health, Organization, Environment, Chrysotile, Social, Personal protective equipment, Public health, Convention, Economic development, Oil, Arctic

They deemed it necessary to organize an international conference where measures to protect the industrial use of chrysotile asbestos from discriminations would be developed.

Key Points: 
  • They deemed it necessary to organize an international conference where measures to protect the industrial use of chrysotile asbestos from discriminations would be developed.
  • Chrysotile asbestos is a fibrous mineral widely used in industrial production.
  • However, the industrial use of chrysotile asbestos is regularly opposed by several states and activists during the Conference of Parties of Rotterdam convention.
  • In 2019, the chrysotile industry weathered a storm and stood proud opponents of asbestos failed to provide convincing evidence.